{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=96",
    "query": {
      "condition": "High-Risk",
      "page": 96
    },
    "page_size": 10
  },
  "pagination": {
    "page": 96,
    "page_size": 10,
    "total_count": 7258,
    "total_pages": 726,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=97&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High-Risk&page=95&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T06:41:37.095Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00126607",
      "title": "Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-grade Salivary Gland Mucoepidermoid Carcinoma",
        "Recurrent Salivary Gland Cancer",
        "Salivary Gland Acinic Cell Tumor",
        "Salivary Gland Adenocarcinoma",
        "Salivary Gland Poorly Differentiated Carcinoma",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVC Salivary Gland Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126607"
    },
    {
      "nct_id": "NCT05675345",
      "title": "Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Hypoxemic Respiratory Failure"
      ],
      "interventions": [
        {
          "name": "HFNC only",
          "type": "DEVICE"
        },
        {
          "name": "HFNC + CNEP10",
          "type": "DEVICE"
        },
        {
          "name": "HFNC + CNEP20",
          "type": "DEVICE"
        },
        {
          "name": "HFNC + CNEP30",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-02-28",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 4,
      "location_summary": "Brooklyn, New York • New York, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05675345"
    },
    {
      "nct_id": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Carcinoma (NSCLC)",
        "Renal Cell Carcinoma (RCC)",
        "Small-cell Lung Cancer",
        "Head and Neck Squamous Cell Cancer",
        "Classical Hodgkin Lymphoma",
        "Primary Mediastinal Large B-Cell Lymphoma",
        "Urothelial Carcinoma",
        "Microsatellite Instability-High Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Merkel Cell Carcinoma",
        "Brain Metastases, Adult"
      ],
      "interventions": [
        {
          "name": "LITT + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-01-10",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Jacksonville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04187872"
    },
    {
      "nct_id": "NCT04008030",
      "title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 839,
      "start_date": "2019-08-05",
      "completion_date": "2027-03-23",
      "has_results": true,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04008030"
    },
    {
      "nct_id": "NCT01313507",
      "title": "High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency Disease"
      ],
      "interventions": [
        {
          "name": "NewGam",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2011-05",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 6,
      "location_summary": "Irvine, California • Centennial, Colorado • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Papillion",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01313507"
    },
    {
      "nct_id": "NCT01190631",
      "title": "An Assessment of Residual Spherical Aberration, Postoperative Total High Order Aberrations, and Functional Vision Correlation Following Intraocular Lens (IOL) Implantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "Acrysof IQ (SN60WF) IOL",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-11-29",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190631"
    },
    {
      "nct_id": "NCT03647475",
      "title": "A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Medtronic Vascular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 752,
      "start_date": "2018-10-01",
      "completion_date": "2021-04-22",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 4,
      "location_summary": "East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more",
      "locations": [
        {
          "city": "East Syracuse",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03647475"
    },
    {
      "nct_id": "NCT00778375",
      "title": "Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2008-10",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00778375"
    },
    {
      "nct_id": "NCT01874119",
      "title": "Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chemotherapy-induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "Fosaprepitant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-09",
      "completion_date": "2015-12-03",
      "has_results": true,
      "last_update_posted_date": "2018-06-07",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01874119"
    },
    {
      "nct_id": "NCT02152956",
      "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "AML"
      ],
      "interventions": [
        {
          "name": "Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 244,
      "start_date": "2014-06-09",
      "completion_date": "2022-07-05",
      "has_results": true,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-11-07T06:41:37.095Z",
      "location_count": 20,
      "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02152956"
    }
  ]
}